These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 22455745)

  • 1. [Clinical value of combined detection of serum human epididymal secretory protein E4 and CA(125) in the diagnosis of endometrial carcinoma].
    Zhang AM; Zhang P
    Zhonghua Fu Chan Ke Za Zhi; 2012 Feb; 47(2):125-8. PubMed ID: 22455745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
    Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
    Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Diagnostic value of combining detection of human epididymis protein 4 and CA125 in patients with malignant ovarian carcinoma].
    Wang MJ; Qi J; Wang H; Li XX; Wei BJ; Fu C; Gao J; Han BB
    Zhonghua Zhong Liu Za Zhi; 2011 Jul; 33(7):540-3. PubMed ID: 22093635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of serum human epididymis protein 4 and cancer antigen 125 concentrations in endometrial carcinoma.
    Saarelainen SK; Peltonen N; Lehtimäki T; Perheentupa A; Vuento MH; Mäenpää JU
    Am J Obstet Gynecol; 2013 Aug; 209(2):142.e1-6. PubMed ID: 23583212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CA125 and HE4 levels in a Czech female population diagnosed with endometrial cancer in preoperative management.
    Presl J; Novotny Z; Topolcan O; Vlasak P; Kucera R; Fuchsova R; Vrzalova J; Betincova L; Svobodova S
    Anticancer Res; 2014 Jan; 34(1):327-31. PubMed ID: 24403483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of HE4 as an extrabiomarker to CA125 to improve detection of ovarian carcinoma: is it time for a step forward?
    Azzam AZ; Hashad DI; Kamel NA
    Arch Gynecol Obstet; 2013 Jul; 288(1):167-72. PubMed ID: 23361457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a multimarker assay for differential diagnosis of benign and malignant pelvic masses.
    Chen X; Zhou H; Chen R; He J; Wang Y; Huang L; Sun L; Duan C; Luo X; Yan H
    Clin Chim Acta; 2015 Feb; 440():57-63. PubMed ID: 25447698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TATI (tumor associated trypsin inhibitor) and cancer antigen 125 (CA 125) in patients with early-stage endometrial cancer.
    Peters-Engl C; Buxbaum P; Ogris E; Sevelda P; Medl M
    Anticancer Res; 1998; 18(6B):4635-9. PubMed ID: 9891532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HE4 and CA125 levels in the preoperative assessment of endometrial cancer patients: a prospective multicenter study (ENDOMET).
    Antonsen SL; Høgdall E; Christensen IJ; Lydolph M; Tabor A; Loft Jakobsen A; Fagö-Olsen CL; Andersen ES; Jochumsen K; Høgdall C
    Acta Obstet Gynecol Scand; 2013 Nov; 92(11):1313-22. PubMed ID: 24032654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of novel biomarker HE4 in endometrial cancer: a case control prospective study.
    Angioli R; Plotti F; Capriglione S; Montera R; Damiani P; Ricciardi R; Aloisi A; Luvero D; Cafà EV; Dugo N; Angelucci M; Benedetti-Panici P
    Tumour Biol; 2013 Feb; 34(1):571-6. PubMed ID: 23179397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum HE4 as a prognostic marker in endometrial cancer--a population based study.
    Brennan DJ; Hackethal A; Metcalf AM; Coward J; Ferguson K; Oehler MK; Quinn MA; Janda M; Leung Y; Freemantle M; ; Webb PM; Spurdle AB; Obermair A
    Gynecol Oncol; 2014 Jan; 132(1):159-65. PubMed ID: 24211402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HE4 is an independent prognostic marker in endometrial cancer patients.
    Mutz-Dehbalaie I; Egle D; Fessler S; Hubalek M; Fiegl H; Marth C; Widschwendter A
    Gynecol Oncol; 2012 Aug; 126(2):186-91. PubMed ID: 22525819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Significance of Serum HE4, CA125, CA724, and CA19-9 in Patients With Endometrial Cancer.
    Bian J; Sun X; Li B; Ming L
    Technol Cancer Res Treat; 2017 Aug; 16(4):435-439. PubMed ID: 27562869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel algorithm including CA-125, HE4 and body mass index in the diagnosis of endometrial cancer.
    Knific T; Osredkar J; Smrkolj Š; Tonin I; Vouk K; Blejec A; Frković Grazio S; Rižner TL
    Gynecol Oncol; 2017 Oct; 147(1):126-132. PubMed ID: 28735628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Measurement of serum human epididymis secretory protein 4 combined with CA125 assay in differential diagnosis of endometriosis cyst and ovarian benign and malignant tumors].
    Liu YN; Ye X; Cheng HY; Cheng YX; Fu TY; Chen J; Chang XH; Cui H
    Zhonghua Fu Chan Ke Za Zhi; 2010 May; 45(5):363-6. PubMed ID: 20646446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative serum CA-125 levels in treating endometrial cancer.
    Powell JL; Hill KA; Shiro BC; Diehl SJ; Gajewski WH
    J Reprod Med; 2005 Aug; 50(8):585-90. PubMed ID: 16220763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum HE4 detects recurrent endometrial cancer in patients undergoing routine clinical surveillance.
    Brennan DJ; Hackethal A; Mann KP; Mutz-Dehbalaie I; Fiegl H; Marth C; Obermair A
    BMC Cancer; 2015 Feb; 15():33. PubMed ID: 25655024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of HE4 to identify patients with endometrioid endometrial cancer who may require lymphadenectomy.
    Dobrzycka B; Mackowiak-Matejczyk B; Terlikowska KM; Kinalski M; Terlikowski SJ
    Adv Med Sci; 2016 Mar; 61(1):23-7. PubMed ID: 26344910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses.
    Abdel-Azeez HA; Labib HA; Sharaf SM; Refai AN
    Asian Pac J Cancer Prev; 2010; 11(1):111-6. PubMed ID: 20593939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
    Riisbro R; Stephens RW; Brünner N; Christensen IJ; Nielsen HJ; Heilmann L; von Tempelhoff GF
    Gynecol Oncol; 2001 Sep; 82(3):523-31. PubMed ID: 11520150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.